News & Events about Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) CEO Thomas A. Mccourt sold 110,962 shares of the companys stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of the ...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) CEO Thomas A. Mccourt sold 110,962 shares of the companys stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of...
Blueshift Asset Management LLC reduced its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) by 16.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,354 shares of the biotechnology ...
Aaron Wealth Advisors LLC bought a new stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,648 shares of the ...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) CEO Thomas A. Mccourt sold 36,308 shares of the firms stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $11.50, for a total value of $417,542.00. Following the completion of the sale, the chief executive ...